GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Society of Hematology  (2)
  • Gentilini, Chiara  (2)
  • Medicine  (2)
Material
Publisher
  • American Society of Hematology  (2)
Language
Years
Subjects(RVK)
  • Medicine  (2)
RVK
  • 1
    In: Blood, American Society of Hematology, Vol. 106, No. 11 ( 2005-11-16), p. 2906-2906
    Abstract: NK cell alloreactivity can mediate strong graft versus leukemia (GvL) effects following haploidentical hematopoietic stem cell transplantation (HSCT). In an attempt to further improve the antileukemic effectiveness of this approach, we have adoptively transferred high numbers of alloreactive donor NK cells during the early phase after transplantation. Method: In a phase-II study, 10 patients (6 AML, 1 MDS, 1 HD, 1 CML, 1 ALL, median age 38 yrs, range 17–48 yrs) were transplanted in late phases of their disease (5 pts. as 2nd transplantation) and received purified NK cells from their haploidentical donors at day +2 after HSCT. Conditioning consisted of 12 Gy fTBI, Thiotepa (10mg/kg), Fludarabine (5 x 30 mg/qm) and OKT3 (day −4 to +2). Two patients received a reduced conditioning with Fludarabine and OKT3 alone. NK cells were isolated from the CD34- fraction using an automated two-step procedure of CD3+ depletion and subsequent CD56+ selection. Results: No severe technical problems occurred and a mean of 12,1 x 10E8 (16,74 x10E6/kg, range 6,12 to 27,2 x10E6/kg) CD34+ cells was selected in high purity (95,9 %) with a very low T-cell content (mean 1,83 x10E4/kg CD3+ cells, 4,5 Log depletion). A mean of 5,7 x10E8 (6,7 x 10E6/kg) CD56+CD3− NK cells was transferred (yield 70,36%, purity 70%). The mean number of contaminating CD3+ cells was 3,2 x10E4/kg (3,6 Log depletion).No severe acute toxicity attributable to NK cell infusion was observed. Hematopoietic recovery was fast with leukocytes & gt; 1/nl between day 5 and 11. Seven patients developed early grade II GvHD of the skin which promptly resolved after CSA and steroids. One patient developed late graft rejection five months after reduced conditioning, received a 2nd graft from a different donor, engrafted but unfortunately died due to pneumonia one month after the second transplantation. One pt with CML died due to adenovirus infection at day 140. One pt. with HD in 5th CR died due to pneumonia at day 85. One patient showed a relapse of the AML three months after transplant. She received a DLI with NK cells form the donor but died due to disease progression one month after. Interestingly, leukemic cells from this patient proved to be resistant to donor NK cell mediated lysis. Five of 9 patients are alive and in CCR with a median follow up of 192 days, the two patients with the longest follow up are in very good condition and free of GvHD at day +1271 and +1019. Our data show for the first time that the early adoptive transfer of high numbers of HLA-mismatched NK cells is safe and feasible.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2005
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 110, No. 11 ( 2007-11-16), p. 354-354
    Abstract: To improve the antileukemic effectiveness of haploidentical stem cell transplantation (HSCT) and strengthen the cell mediated immune response, we have adoptively transferred high numbers of alloreactive donor NK cells during the early phase after transplantation. In addition, we activated the transferred NK-cell population ex vivo in short term cultures with high doses of IL-2 in order to enhance the antileukemic activity and inhibit the occurrence of severe GvHD. Method: In a phase-II study, 17 patients (10 AML, 1 MDS, 1 HD, 2 CML, 3 ALL, median age 37 yrs, range 17–48 yrs) were transplanted in late phases of their disease (6 pts. as 2nd transplantation) and received purified NK cells from their haploidentical donors at day +2 after HSCT. Conditioning consisted of 12 Gy fTBI, Thiotepa (10mg/kg), Fludarabine (5 x 30 mg/qm) and OKT3 (day −4 to +2). NK cells were isolated from the CD34- fraction using an automated two-step procedure of CD3+ depletion and subsequent CD56+ selection. Seven patients received activated NK cells and 10 patients received unstimulated NK cells. Cells were activated by 16h incubation with IL-2 (500U/1x107 cells). Results: After selection and subsequent overnight activation of the NK cells with IL-2 (7 out of 17 patients), a mean number of 8.3 x 106/kg CD56+CD3− NK cells was transferred at day 2 after transplantation. The purity was 76%, due to contaminating CD56+ monocytes. The mean number of contaminating CD3+ cells in the transfused NK product was 2.1 x 104/kg. Activation of donor NK cells with IL-2 resulted in an increase of cytotoxic activity, when cells were tested against target cell lines. No differences in yield or number of contaminating T cells were observed between IL-2 activated and not activated NK cells. No severe acute toxicity attributable to NK cell infusion was observed in both groups of patients. Comparing the rate of high-grade GvHD revealed an interesting result. Whereas only one patient developed GvHD ≥ grade II after treatment with IL-2 activated NK cells, seven out of ten patients showed GvHD ≥ grade II after transfer of non-activated NK cells (p 〈 0.05). When the correlation between GvHD and the presence of a KIR mismatch was analyzed no significant difference was observed. Moreover immunocytometric analysis of lymphocyte subpopulations at different time points after transplant revealed a long-lasting cellular immunodeficiency in all patients, with slow recovery of CD4+ lymphocytes. As for the incidence of GvHD, there was also a striking difference in immune recovery between the patients receiving IL2-activated and those treated with non-activated NK cells. Patients receiving activated NK cells showed significantly lower numbers of NK- and T cells during the first months post transplant, whereas no differences in the number of granulocytes were present between the two groups. Based on these findings we can assume that the use of IL-2 for NK cell activation could play a role in reducing the incidence of severe GvHD after haploidentical HSCT.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2007
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...